Sage Therapeutics, Inc. (SAGE) Forecasted to Post FY2018 Earnings of ($6.70) Per Share
Sage Therapeutics, Inc. (NASDAQ:SAGE) – Research analysts at William Blair cut their FY2018 earnings estimates for shares of Sage Therapeutics in a note issued to investors on Tuesday. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will post earnings of ($6.70) per share for the year, down from their previous estimate of ($6.03). William Blair also issued estimates for Sage Therapeutics’ FY2019 earnings at ($5.15) EPS.
Several other analysts also recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Sage Therapeutics in a report on Thursday. They issued an “outperform” rating and a $117.00 target price for the company. BMO Capital Markets lifted their target price on shares of Sage Therapeutics from $80.00 to $84.00 and gave the company an “outperform” rating in a report on Thursday. Chardan Capital reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday. Needham & Company LLC dropped their target price on shares of Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $91.00 target price (down previously from $104.00) on shares of Sage Therapeutics in a report on Wednesday. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Sage Therapeutics has an average rating of “Buy” and an average target price of $86.77.
Shares of Sage Therapeutics (NASDAQ:SAGE) opened at 62.36 on Thursday. The firm’s 50-day moving average price is $81.33 and its 200 day moving average price is $74.82. The company’s market capitalization is $2.33 billion. Sage Therapeutics has a 52 week low of $38.30 and a 52 week high of $90.80.
Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same period in the prior year, the company earned ($1.08) earnings per share.
Large investors have recently bought and sold shares of the business. State of Wisconsin Investment Board acquired a new position in shares of Sage Therapeutics in the second quarter worth $1,991,000. Teacher Retirement System of Texas acquired a new position in shares of Sage Therapeutics in the second quarter worth $202,000. Schwab Charles Investment Management Inc. grew its stake in shares of Sage Therapeutics by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 131,440 shares of the biopharmaceutical company’s stock worth $9,342,000 after acquiring an additional 1,593 shares in the last quarter. Spark Investment Management LLC acquired a new position in shares of Sage Therapeutics in the first quarter worth $4,086,000. Finally, Rhumbline Advisers grew its stake in shares of Sage Therapeutics by 9.4% in the second quarter. Rhumbline Advisers now owns 41,138 shares of the biopharmaceutical company’s stock worth $3,276,000 after acquiring an additional 3,551 shares in the last quarter.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.